Kidney cancer
China approves fruquintinib combination for kidney cancer
May 29, 2026Kidney cancer, Nephrology
China’s National Medical Products Administration (NMPA) has approved a combination of ELUNATE (fruquintinib) and TYVYT (sintilimab) for patients with advanced …
FDA approves AVEO’s kidney cancer treatment
March 11, 2021Aveo, FDA, Kidney cancer, fotivda, rcc
The FDA has approved AVEO Oncology’s FOTIVDA drug for the treatment of adults with relapsed or refractory advanced renal cell …
Keytruda rejected for NHS use for bladder cancer, will be removed from the Cancer Drugs Fund
March 12, 2020Sales and Marketing Cancer, Kidney cancer, MSD, NHS, NICE, blader cancer, keytruda, pharma
MSD’s blockbuster immunotherapy Keytruda (pembrolizumab) has been knocked back by NICE for use on the NHS as a treatment for …
Eisai releases new Phase 2 data for levatinib+everolimus combo in advanced kidney cancer
February 17, 2020Research and Development, Sales and Marketing Cancer, Eisai, Kidney cancer, Lenvima, pharma, renal cell carcinoma
New Phase 2 data has been revealed for Eisai’s Lenvima (levatinib), delivered alongside Novartis’ everolimus, for the treatment of unresectable …
NICE does not recommend cancer drug combination to the NHS
February 13, 2020Business Services Cancer, Kidney cancer, NHS, NICE, keytruda, kidney disease
NICE has published draft guidance that does not recommend a new drug combination to combat untreated advanced renal cell carcinoma …
Bavencio+Inlyta combo OK’d in Europe for first-line advanced kidney cancer
October 29, 2019Manufacturing and Production, Sales and Marketing Bavencio, Cancer, Kidney cancer, Merck KGaA, Pfizer, inlyta, pharma
Merck KGaA and Pfizer’s joint drug Bavencio (avelumab) has received European approval in combination with Inlyta (axitinib) in the first-line …
BMS Opdivo/Yervoy recommended for untreated kidney cancer via Cancer Drugs Fund
April 5, 2019Medical Communications, Sales and Marketing CDF, Cancer, Cancer Drugs Fund, Kidney cancer, NICE, UK, Yervoy, opdivo
NICE has revealed it is recommending that Bristol-Myers Squibb’s Opdivo (nivolumab), in combination with Yervoy (ipilimumab), be made available to …
Bavencio+Inlyta combo boosts progression-free survival in advanced kidney cancer
February 18, 2019Research and Development, Sales and Marketing Bavencio, Cancer, Kidney cancer, Merck KGaA, Pfizer, inlyta, pharma
New interim data for the combination of Pfizer’s Bavencio (avelumab) and Merck KGaA’s Inlyta (axitinib) have been released, showing that …
Half of kidney cancer patients initially misdiagnosed
October 30, 2018Manufacturing and Production Cancer, Kidney cancer, NHS, UK, diagnosis
Half of kidney cancer patients are initially misdiagnosed, according to data from Kidney Cancer UK’s patient survey. Despite being the …
MSD’s Keytruda with Pfizer’s Inlyta beats Sutent in most common kidney cancer
October 19, 2018Medical Communications, Research and Development Cancer, Kidney cancer, MSD, Pfizer, inlyta, keytruda, pharma
MSD has unveiled new Phase 3 data on its blockbuster anti-PD-1 cancer therapy Keytruda (pembrolizumab) as part of a combination, …
Merck KGaA and Pfizer’s combo impresses in first-line treatment of advanced kidney cancer
September 12, 2018Research and Development, Sales and Marketing Cancer, Kidney cancer, Merck KGaA, Pfizer, pharma
Bavencio (avelumab), Merck KGaA and Pfizer’s human anti-programmed death ligand-1 (PD-L1) antibody, combined with the latter’s Inlyta (axitinib) has shown …
Evolutionary path of kidney cancer tracked, “born to be bad” type discovered
April 13, 2018Medical Communications, Research and Development Kidney cancer, biotech, drugs, pharma, pharmaceutical
A massive effort funded by Cancer Research UK has been able to track the different evolutionary pathways of kidney cancer …
Pfizer shuts down kidney cancer drug trial due to “futility”
April 11, 2018Research and Development Cancer, Kidney cancer, Pfizer, inlyta, pharma
Pfizer has revealed that it has shut down a trial of its vascular endothelial growth factor (VEGF) inhibitor Inlyta (axitinib) …
Eisai and MSD team up to combine Lenvima and Keytruda in cancer
March 8, 2018Sales and Marketing Cancer, Eisai, Kidney cancer, Lenvima, MSD, Merck, keytruda, pharma
Pharma heavyweights MSD (Merck) and Eisai have announced they are to join forces to develop and commercialise the latter’s tyrosine …
FDA expands use of Pfizer’s Sutent in kidney cancer
November 17, 2017Medical Communications, Sales and Marketing Cancer, Kidney cancer, Pfizer, Sutent, pharma
Pfizer has announced that the FDA has expanded the use of its tyrosine kinase inhibitor Sutent (sunitinib malate) to include …
Latest content
FibroFind appoints Lee Borthwick as CEO
